Objective: The most typical cytogenetic aberration in myelodysplastic syndromes is del(5q), which, when isolated, is associated with refractory anaemia and good prognosis. Based on high rates of erythroid response and transfusion independence, Lenalidomide (LEN) became the standard treatment. This multi-centre study was designed to supplement Italian Registry data on LEN by addressing prescription, administration appropriateness, haematological and cytogenetic responses and disease evolution. Methods: MORE study was an observational, non-interventional, multi-centre, retrospective and prospective study. Cases were recruited from 45 Haematological Centres throughout Italy. Data were collected from the Italian National Registry for Lenalidomide administration and supplemented by a MORE data form. Results: Data from 190/213 patients were analysed. In all, 149 had been diagnosed by conventional cytogenetics (GROUP A) and 41 only by FISH (GROUP B). Overall erythroid response was obtained in 92.8% of cases. Overall cytogenetic remission was achieved in 22.6% of cases. Disease progression occurred in 15.6% of cases. Clonal cytogenetic evolution characterised progression to AML but not to higher risk MDS. Conclusions: Erythroid response to Lenalidomide was similar in MDS with isolated del(5q) and with del(5q) plus one anomaly. Progression to AML or higher risk MDS showed different cytogenetic features.

Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency

Lanza F.
Investigation
;
2018

Abstract

Objective: The most typical cytogenetic aberration in myelodysplastic syndromes is del(5q), which, when isolated, is associated with refractory anaemia and good prognosis. Based on high rates of erythroid response and transfusion independence, Lenalidomide (LEN) became the standard treatment. This multi-centre study was designed to supplement Italian Registry data on LEN by addressing prescription, administration appropriateness, haematological and cytogenetic responses and disease evolution. Methods: MORE study was an observational, non-interventional, multi-centre, retrospective and prospective study. Cases were recruited from 45 Haematological Centres throughout Italy. Data were collected from the Italian National Registry for Lenalidomide administration and supplemented by a MORE data form. Results: Data from 190/213 patients were analysed. In all, 149 had been diagnosed by conventional cytogenetics (GROUP A) and 41 only by FISH (GROUP B). Overall erythroid response was obtained in 92.8% of cases. Overall cytogenetic remission was achieved in 22.6% of cases. Disease progression occurred in 15.6% of cases. Clonal cytogenetic evolution characterised progression to AML but not to higher risk MDS. Conclusions: Erythroid response to Lenalidomide was similar in MDS with isolated del(5q) and with del(5q) plus one anomaly. Progression to AML or higher risk MDS showed different cytogenetic features.
Arcioni, F.; Roncadori, A.; Di Battista, V.; Tura, S.; Covezzoli, A.; Cundari, S.; Mecucci, C.; Abbadessa, A.; Alterini, R.; Santini, V.; Cantonetti, M.; Buccisano, F.; Bacigalupo, A.; Sessarego, M.; Tonso, A.; Ferrero, D.; D'Ardia, S.; Tarella, C.; Cascavilla, N.; Bassan, R.; Sancetta, R.; Cortelezzi, A.; Reda, G.; Maria D'Arco, A.; De Fabritiis, P.; Di Renzo, N.; Falini, B.; Alimena, G.; Avanzini, P.; Ilariucci, F.; Iuliano, F.; La Nasa, G.; Caocci, G.; Defina, M.; Latte, G.; Palmas, A.; Levis, A.; Leone, G.; Teresa Voso, M.; Leoni, P.; Poloni, A.; Fozza, C.; Crugnola, M.; Montanaro, M.; Spedini, P.; Lanza, F.; Pizzuti, M.; Pane, F.; Paolini, R.; Borin, L.; Rambaldi, A.; Rossi, G.; Maria Pelizzari, A.; Russo, D.; D'Emilio, A.; Ruggeri, M.; Semenzato, G.; Specchia, G.; Tagariello, G.; Sartori, R.; Testore, F.; Ciravegna, G.; Marasca, R.; Cimarosto, L.; Fontanive, O.; Visani, G.
File in questo prodotto:
File Dimensione Formato  
Lenalidomide mieloma 2018 EJH 13067.pdf

solo gestori archivio

Descrizione: Full text editoriale
Tipologia: Full text (versione editoriale)
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 537.72 kB
Formato Adobe PDF
537.72 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
ejh.13067.pdf

solo gestori archivio

Descrizione: Full text editoriale
Tipologia: Full text (versione editoriale)
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 527.23 kB
Formato Adobe PDF
527.23 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
arcioni2018.pdf

accesso aperto

Descrizione: Post print
Tipologia: Post-print
Licenza: PUBBLICO - Pubblico con Copyright
Dimensione 453.19 kB
Formato Adobe PDF
453.19 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2416141
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact